Skip to content
10-Q

Quarterly Report

NEXIEN BIOPHARMA, INC.

0001493152-23-017925

← back to feed
Filed
May 17, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · May 15, 2023 63.52M sh
Cash And Equivalents Q3 2023 · Mar 31, 2023 $54.21K
Cash And Equivalents Q3 2023 · Jun 30, 2022 $116.9K
Current Liabilities Q3 2023 · Mar 31, 2023 $288.5K
Current Liabilities Q3 2023 · Jun 30, 2022 $242.12K
Total Liabilities Q3 2023 · Mar 31, 2023 $288.5K
Total Liabilities Q3 2023 · Jun 30, 2022 $242.12K
Current Assets Q3 2023 · Mar 31, 2023 $58.2K
Current Assets Q3 2023 · Jun 30, 2022 $124.52K
Total Assets Q3 2023 · Mar 31, 2023 $58.2K
Total Assets Q3 2023 · Jun 30, 2022 $124.52K
Operating Cash Flow Q3 2023 · Mar 31, 2022 −$51.82K
Stockholders Equity Q3 2023 · Mar 31, 2022 −$63.26K
Stockholders Equity Q3 2023 · Dec 31, 2021 −$62.43K
Stockholders Equity Q3 2023 · Sep 30, 2021 −$39.99K
Stockholders Equity Q3 2023 · Jun 30, 2021 −$13.78K
Eps Basic Q3 2023 · Mar 31, 2022 −$0.00
Eps Basic Q3 2023 · Mar 31, 2022 −$0.01
Sga Expense Q3 2023 · Mar 31, 2022 $153.11K
Sga Expense Q3 2023 · Mar 31, 2022 $464.07K
Net Income Q3 2023 · Mar 31, 2022 −$187.45K
Net Income Q3 2023 · Mar 31, 2022 −$529.36K
Net Income Q3 2023 · Dec 31, 2021 −$220.19K
Net Income Q3 2023 · Sep 30, 2021 −$121.71K